PDCD1 and pancreatic neoplasm: In a PD1-mAb-resistant mouse model of pancreatic cancer, pharmacological inhibition of CXCR2 synergized with anti-PD1 therapy to significantly extend survival, while genetic deletion or inhibition of CXCR2 increased T-cell infiltration into the TME.